The Manufacturers' Perspective on World Health Organization Prequalification of in Vitro Diagnostics

Sébastien Morin, Nelli Bazarova, Philippe Jacon, Stefano Vella

Research output: Contribution to journalReview articlepeer-review


In vitro diagnostic devices (IVDs) help clinicians determine specific conditions, monitor therapeutic efficacy, and prevent drug resistance development. While stringent regulatory authorities (SRAs) regulate IVDs in most high-income countries, regulatory authorities in many low-and middle-income countries (LMICs) are nonexistent or do not enforce rigorous standards. In 2010, the World Health Organization established its Prequalification of In Vitro Diagnostics (PQDx) program to ensure "access to safe, appropriate and affordable" IVDs, especially in LMICs with little or no domestic regulatory frameworks, thereby reaching underserved populations. However, challenges in PQDx policies and procedures include an overloaded pipeline, timelines not publicly available, confusion about which products PQDx focuses on, perceived burden for documenting changes to prequalified products, overlap with SRA approvals, and uncertainty around long-Term financing. PQDx can maximize its impact by considering the perspective of IVD manufacturers; similarly, IVD manufacturers should exercise adequate quality control over their submissions and associated processes.

Original languageEnglish
Pages (from-to)301-305
Number of pages5
JournalClinical Infectious Diseases
Issue number2
Publication statusPublished - Jan 15 2018


  • in vitro diagnostics
  • low-and middle-income countries
  • prequalification
  • regulatory environment
  • World Health Organization

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'The Manufacturers' Perspective on World Health Organization Prequalification of in Vitro Diagnostics'. Together they form a unique fingerprint.

Cite this